Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Artificial Pancreas Limits Diabetes Blood-Sugar Swings in Study

Don't Miss Out —
Follow us on:

Feb. 27 (Bloomberg) -- An artificial pancreas device can help control the level of blood-sugar in young diabetics at night, when the most severe declines tend to occur, better than a standard method, a study shows.

As many as 56 patients 10 to 18 years old and suffering from type 1 diabetes were tested with the MD-Logic artificial pancreas made by researchers and, on alternate nights, an insulin pump linked to a glucose sensor. There were 7 events of night-time hypoglycemia as defined by European guidelines with the experimental device and 22 with the pump, according to the study published in the New England Journal of Medicine.

Sanofi, maker of the insulin Lantus, helped fund the research.

To contact the reporter on this story: Marthe Fourcade in Paris at mfourcade@bloomberg.net

To contact the editor responsible for this story: David Risser at drisser@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.